Trial Profile
Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 16 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Dec 2024.
- 02 May 2023 Planned End Date changed from 1 Dec 2022 to 1 Jan 2024.
- 13 Apr 2020 Planned primary completion date changed from 1 Feb 2020 to 1 Dec 2022.